Related Experiment Videos
[Arrhythmias in chronic heart failure. Prognostic significance and treatment]
A Koenig1, M Chauvin, D Thévenin
1Service de Cardiologie, CMCO, Schiltigheim.
Insights
Sudden cardiac death is common in chronic heart failure patients, often caused by arrhythmias. Beta-blockers and amiodarone are valuable treatments for dangerous ventricular arrhythmias, improving prognosis.
Area of Science:
- Cardiology
- Cardiac Electrophysiology
- Pharmacology
Context:
- Chronic heart failure (CHF) patients have a high risk of sudden cardiac death, frequently linked to arrhythmias.
- Prognosis in CHF is influenced by myocardial damage and ventricular arrhythmias.
- Assessing ventricular arrhythmia severity involves ECG, Holter monitoring, late potentials, and programmed ventricular stimulation.
Purpose:
- To explore therapeutic strategies for improving prognosis in chronic heart failure patients.
- To identify effective treatments for potentially dangerous ventricular arrhythmias in CHF.
- To evaluate the role of antiarrhythmic agents in managing CHF complications.
Summary:
- Nearly 50% of chronic heart failure patients experience sudden death, primarily due to arrhythmias.
- Improving myocardial function with converting enzyme inhibitors is a primary therapeutic step.
- Beta-blockers and amiodarone are identified as valuable antiarrhythmic agents for managing ventricular arrhythmias.
Impact:
- This research highlights critical therapeutic targets for reducing mortality in chronic heart failure.
- It emphasizes the importance of managing ventricular arrhythmias alongside myocardial function improvement.
- The findings guide clinical practice towards effective antiarrhythmic drug selection for CHF patients.
Abstract:
Almost 50 percent of patients with chronic heart failure die of sudden death often due to arrhythmia. In these patients the prognosis is related to the severity of myocardial lesions and also, probably, to the presence of ventricular arrhythmias. The potential severity of which can be assessed by various methods, including ECG, Holter monitoring, late potentials study and programmed ventricular stimulation tests. The first therapeutic measure to improve the prognosis of heart failure is to improve the myocardial function by prescribing converting enzyme inhibitors. The second measure consists of acting on potentially dangerous ventricular arrhythmias with few or no symptoms. Among antiarrhythmic agents, only beta-blockers and amiodarone seem to be valuable.